Genomics startup NanoString files for IPO in spite of consistent losses
Not content with the research side, NanoString places a lot of emphasis on its technology's usefulness in clinical settings for present-day patient care. Unfortunately, one of the biggest risk factors for this IPO is the company's consistent losses.









